Syntekabio signe un contrat de découverte de composés anticancéreux — ciblant le marché de développement de médicaments par IA de 6 000 milliards de KRW

[PharmNews] Syntekabio is tightening its grip on the AI développement de médicaments market, projected to grow to KRW 6 trillion annually by 2027.

Syntekabio (226330, CEO Jongsun Jeong), an AI-based développement de médicaments company, a annoncé avoir signed a KRW 400 million développement de médicaments contrat with RudaCure (PDG Yongho Kim), une entreprise spécialisée dans le développement de traitements pour les troubles sensoriels. The two companies plan to develop new anticancer substances by May 31, 2026.

This contrat follows the recent candidat-médicament discovery accord with a NASDAQ-listed company in the US last November, marking consecutive achievements.

Syntekabio assesses that these two contrats have laid the foundation for securing KRW 3 billion in revenue l'année prochaine. This is significatif as KOSDAQ-listed companies with annual revenue below KRW 3 billion may face administrative issues.

An industrie insider a déclaré : "Syntekabio's consecutive contrat achievements are evidence that the AI développement de médicaments market is entering full-scale growth. Through collaboration with companies like RudaCure, AI développement de nouveaux médicaments devrait generate practical outcomes."

팜뉴스

프라임경제